![]() |
市場調查報告書
商品編碼
2049312
尼古丁口香糖市場報告:按類型、應用、分銷管道和地區分類(2026-2034 年)Nicotine Gum Market Report by Type, Application, Distribution Channel, and Region 2026-2034 |
||||||
2025年,全球尼古丁口香糖市場規模達17.6億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到25.3億美元,2026年至2034年的複合年成長率(CAGR)為3.95%。推動全球市場成長的因素有很多,包括戒菸力度加大、健康意識增強以及消費者對便捷的非處方尼古丁替代療法的需求增加。此外,提升產品功效的技術創新也為市場增添了顯著價值。
戒菸努力和健康意識
全球範圍內減少吸煙的努力和日益增強的健康意識正在推動市場擴張。隨著人們對吸菸相關健康風險的認知不斷提高,他們正積極尋求有效的戒菸方法。尼古丁口香糖是戒煙輔助劑,它透過緩慢、可控地釋放尼古丁來緩解戒斷症狀。此外,醫療機構和監管機構所進行的各種戒菸計畫也為尼古丁口香糖的需求創造了有利環境。對公共衛生的重視以及持續不斷的控煙努力,使得尼古丁口香糖被廣泛接受為戒菸治療的重要組成部分,進一步促進了市場成長。 2023年4月11日,衛生部長尼爾·奧布萊恩在政策交流會上就政府降低吸煙率和解決未成年人使用電子菸問題的計劃發表了講話。
對非處方尼古丁替代療法的需求不斷成長
根據IMARC Group統計,2023年全球非成藥)市場規模達1,687億美元。推動該市場發展的主要因素之一是對非處方尼古丁替代療法的需求不斷成長。這種口香糖是一種易於取得的非處方產品,使用者無需處方箋即可自行使用。其便利性和易用性使其成為許多試圖在不尋求醫療幫助的情況下戒菸的人的首選。人們越來越積極主動地管理自身健康,這為尼古丁口香糖市場帶來了良好的發展前景。此外,2024年1月24日,一項在奧裡薩邦卡托克市斯里拉姆·錢德拉·班賈(SCB)牙科醫學院附屬醫院進行的臨床試驗揭示了戒菸支持領域的一項重大進展,該試驗表明,當尼古丁替代療法(NRT)與行為療法相結合時,戒菸效果顯著。
技術進步與產品創新
尼古丁替代療法配方和給藥方式的持續技術改進和產品創新正在推動市場成長。尼古丁口香糖生產商正加大研發投入,以提高產品功效和使用者體驗。由於口味改良和獨特的給藥系統等創新,使用者正在接受這些口香糖。此外,對尼古丁成癮機制和戒斷症狀的深入了解,也促使人們發展出更有效的口香糖配方。對更有效戒菸方案日益成長的需求正在推動尼古丁口香糖市場的成長。此外,參與企業正在獲得公共機構的產品核准。例如,2023年5月16日,Perigo Company PLC (PRGO) 的尼古丁塗層薄荷錠劑(2毫克和4毫克,非處方藥)獲得了美國食品藥物管理局(FDA) 的最終核准。該產品有助於緩解嘗試戒菸者的戒斷症狀。此外,該產品計劃以零售商自有品牌推出,作為與尼古丁貼片冰薄荷糖類似的同類產品。
The global nicotine gum market size reached USD 1.76 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.53 Billion by 2034, exhibiting a growth rate (CAGR) of 3.95% during 2026-2034. There are various factors that are responsible for the growth of the global market, which include smoking cessation initiatives and heightened health awareness, rising demand for convenient over the counter (OTC) nicotine replacement therapies. Technological innovations for enhancing product efficacy also add significant value to the market.
Smoking Cessation Initiatives and Health Awareness
Global efforts to reduce smoking, along with rising health awareness, are propelling the market expansion. People are actively looking for effective strategies to quit smoking as awareness about health risks connected with smoking increases among them. Nicotine gum is a smoking cessation aid that helps users manage the symptoms of withdrawal by releasing nicotine gradually and under control. In addition, various smoking cessation programs by healthcare organizations and regulatory authorities has created a favorable atmosphere for nicotine gum demand. The rising acceptance of this gum as an essential component of smoking cessation treatments due to the emphasis on public health and the ongoing efforts to eliminate smoking is impelling the market growth. On 11 April 2023, Neil O'Brien, Health Minister, delivered a speech at Policy Exchange on government plans to cut smoking rates and tackle underage vaping,
Growing Demand for OTC Nicotine Replacement Therapies
As per the IMARC Group, in 2023, the size of the OTC medication industry worldwide was US$ 168.7 Billion. One of the main factors propelling the market is the rising demand for OTC nicotine replacement medicines. This gum is an easily available OTC solution that enables users to self-administer therapy without a prescription. This gum's popularity as a top option for people trying to stop smoking without seeking medical help is due to its accessibility and ease of usage. People are becoming more proactive in managing their health, which is offering a positive nicotine gum market outlook. Furthermore, on 24 January 2024, in a significant breakthrough for tobacco cessation efforts, a clinical trial conducted at Sri Ram Chandra Bhanja (SCB) Dental College and Hospital in Cuttack, Odisha, unveiled the remarkable efficacy of nicotine replacement therapy (NRT) when combined with behavioral therapy.
Technological Advancements and Product Innovation
Continuous technological improvements and product innovations in the formulation and administration of nicotine replacement therapies are bolstering the market growth. Nicotine gum companies are spending money on research and development (R&D) activities to enhance the effectiveness of product as well as user experience. Users are adopting these gums owing to innovations like enhanced flavors and unique delivery systems. In addition, enhanced understanding of nicotine addiction and withdrawal processes are benefiting in the creation of gum formulations that are more efficient. The escalating demand for more efficient smoking cessation solutions is bolstering the nicotine gum market growth. Besides this, companies in the market are getting product approvals from the recognized authorities. For instance, Perrigo Company plc (PRGO) received final approval from the Food Drug Administration (FDA) for nicotine coated mint lozenges 2 mg and 4 mg OTC on 16 May 2023. The product helps in reducing withdrawal symptoms in consumers who are trying to quit smoking. Moreover, it will be marketed under retailer's store brand labels as a comparable offering to Nicorette coated ice mint lozenge.
Those looking to cut back on their nicotine intake during their journey to quit smoking can find 2 mg category a suitable choice. 2mg nicotine gum is an ideal alternative for controlling withdrawal symptoms while progressively weaning off nicotine dependence, making it the perfect choice among light to moderate smokers. Furthermore, it is advised for people who need a step-down strategy and in the early phases of quitting in order to enable a more regulated shift to a life free of nicotine.
Medical practice holds the largest share of the industry
Nicotine gums are used in more comprehensive smoking cessation programs in medical settings. Physicians may recommend this gum to patients as part of individualized smoking cessation regimens or during routine consultations. The progressive and regulated release of nicotine from the gum is consistent with evidence-based therapies. In the medical practice application, the importance of healthcare professionals in helping people quit is emphasized, along with the health advantages and individualized assistance that come with using nicotine gum.
Retail pharmacies represent the leading market segment
Nicotine gums are readily available at retail pharmacies. Consumers in search of smoking cessation products can easily locate them in close proximity to their homes. This gum is easily available and pharmacists can offer their advice related to medication, which makes it a favored option for those seeking person-to-person support and quick access to quit smoking products.
North America leads the market, accounting for the largest nicotine gum market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for nicotine gum.
North America stands as a significant market due to robust smoking cessation efforts, heightened health awareness, and a substantial consumer base. The region has a well-established healthcare infrastructure and proactive regulatory measures that contribute to the popularity of these gums as a preferred smoking cessation aid. In addition, there is an increase in the number of individuals seeking effective solutions to quit smoking in the North America region. Besides this, the wide availability of these gum across various distribution channels including retail pharmacies and online stores, assists in increasing nicotine gum market revenue. On 18 March 2024, Cambrex, a leading global contract development and manufacturing organization (CDMO), announced the completion of a 5-year, US$ 100-Million-dollar investment strategy, one year ahead of schedule. The project adds more than 150,000 square-feet of capacity and capability expansions across 70% of its North American and European drug development and manufacturing network, which will be completed by the end of 2024. The investments span all scales of clinical and commercial drug substance manufacturing and include advanced technologies to solve for challenges related to complex molecules.